Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Eric Wu to Costs and Cost Analysis

This is a "connection" page, showing publications Eric Wu has written about Costs and Cost Analysis.

 
Connection Strength
 
 
 
0.447
 
  1. Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. J Med Econ. 2012; 15(6):1078-87.
    View in: PubMed
    Score: 0.089
  2. Wu EQ, Ben-Hamadi R, Yu AP, Tang J, Haim Erder M, Bose A. Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons. J Med Econ. 2010; 13(2):314-23.
    View in: PubMed
    Score: 0.075
  3. Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH. Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. J Med Econ. 2009 Jun; 12(2):124-35.
    View in: PubMed
    Score: 0.072
  4. Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies. J Manag Care Pharm. 2007 Sep; 13(7):561-9.
    View in: PubMed
    Score: 0.064
  5. Liu G, Wu EQ, Ahn J, Kamae I, Xie J, Yang H. The Development of Health Technology Assessment in Asia: Current Status and Future Trends. Value Health Reg Issues. 2020 May; 21:39-44.
    View in: PubMed
    Score: 0.037
  6. Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guérin A. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. Adv Ther. 2016 06; 33(6):983-97.
    View in: PubMed
    Score: 0.029
  7. Yang H, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL. Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States. Appl Health Econ Health Policy. 2014 Feb; 12(1):85-93.
    View in: PubMed
    Score: 0.025
  8. Guérin A, Wu EQ, Bollu VK, Williams D, Guo A, de Leon DP, Quintas-Cardama A. The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Med Econ. 2013; 16(1):125-33.
    View in: PubMed
    Score: 0.022
  9. Yang H, Yu AP, Wu EQ, Yim YM, Yu E. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. J Med Econ. 2011; 14(5):542-52.
    View in: PubMed
    Score: 0.021
  10. Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S. Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med. 2006 Aug; 48(8):794-802.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)